Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Nov
3
2017
Impact of Cyberattack on Merck was $135 million K&L Gates
May
7
2021
HHS Exemptions for Buprenorphine (But not Methadone) Prescribers K&L Gates
Nov
27
2023
Artificial Sweeter Decision Sours Halal Authority: Halal Certification Authority Pty Limited V Flujo Sanguineo Holdings Pty Limited [2023] FCAFC 175 K&L Gates
Jan
25
2024
An Overview of the US Food and Drug Administration's Legislative Goals (Part I) K&L Gates
Jul
27
2020
President Trump Signs Drug Pricing Executive Orders Reinforcing the Administration's Priorities K&L Gates
Sep
26
2020
340B UPDATE: Congress and the Administration Respond to Drug Manufacturers' 340B Contract Pharmacy Actions K&L Gates
Jul
26
2017
Massachusetts’s Highest Court Rules that Employee Fired for Medical Marijuana Use Can Hold Employer Liable for Discrimination K&L Gates
Apr
2
2021
Cannabis Banking; The SAFE Banking Act 2.0's Status, Key Modifications, and Prospects K&L Gates
Mar
17
2022
COVID-19: State Law Telehealth Considerations: State Licensure Requirements Persist, Permissible Telehealth Modalities Generally Expand, and Insurance Parity Laws Ensure Reimbursement (Part 2 of a 3-Part Series) K&L Gates
Apr
18
2022
Litigation Minute: New Bioengineered Food Disclosure Rules and Litigation Risks K&L Gates
Aug
29
2022
Biometric Privacy Statutes and Insurance Coverage: Recent Developments in Illinois and the National Landscape K&L Gates
Sep
26
2022
Issue-Spotting Hospital Activities that May Trigger FDA Regulatory Oversight [PODCAST] K&L Gates
Jan
31
2023
Are Medical Diagnostic Methods Patent Ineligible by Convention?: CareDx, Inc. v. Natera, Inc. and Eurofins Viracor, Inc. K&L Gates
Oct
12
2023
FDA Issues Guidance on Informed Consent for IRBs, Clinical Investigators, and Sponsors [Podcast] K&L Gates
Jul
6
2017
Sandoz v. Amgen – Biosimilars at the U.S. Supreme Court K&L Gates
Aug
28
2017
How Distinctive Can a Chocolate Bar be? After Kit Kat, Now It’s Toblerone’s Turn K&L Gates
Jul
13
2018
Australian Liquor Company may not get Off Scot(ch) Free K&L Gates
Nov
15
2021
Federal Circuit Further Clarifies Venue in Hatch-Waxman Cases K&L Gates
Mar
28
2022
In the Weeds: Why Arbitration May Be the Key to Preserving Enforcement of Cannabis M&A and VC Contracts K&L Gates
Jul
8
2022
Waste Not Want Not: The Impact of EPA's Decision to Consider Reclassifying Discarded Polyvinyl Chloride as A Hazardous Waste K&L Gates
Sep
9
2022
California Legislators Pass Bill Banning Sale of Agricultural Land to Foreign Governments; Increase Ownership Disclosure Requirements K&L Gates
Oct
18
2022
FDA Updates Regulatory Definition of "Healthy" for the First Time Since 1994 K&L Gates
Jul
23
2019
Court Of Chancery Denies Application For Certification Of Interlocutory Appeal After Ruling That Judicial Dissolution Of The Limited Liability Company Is Warranted K&L Gates
Aug
22
2019
In A Reckless Re-Price, Results Are Not Realized K&L Gates
Jun
8
2020
COVID-19: 340B Update: HRSA Updates Guidance Granting New HOPD Flexibility K&L Gates
Jul
18
2019
Producers of Generic Medicines and Biosimilars even More Supported by EU K&L Gates
Dec
8
2016
What a Trump Administration Could Mean for the 340B Drug Program K&L Gates
Feb
26
2024
2023 Health Care Employment Law Year in Review K&L Gates
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins